1. Background {#sec177322}
=============

Liver cancer is one of the most common malignancies in the world. At present, liver transplantation and surgical resection are still the most important treatments for liver cancer, but only a small number of patients receive these treatments in time. Image-guided tumor ablation plays an important role in the treatment of primary and metastatic liver cancer ([@A34588R1], [@A34588R2]). Radiofrequency ablation (RFA) and microwave ablation (MWA) are the most common local thermal ablation methods, and have been widely used in the treatment of liver cancer all over the world ([@A34588R1], [@A34588R2]). The effectiveness of thermal ablation methods for small liver cancers is equivalent to that of surgical resection ([@A34588R3]-[@A34588R5]). Thermal ablation is considered the frontline choice for the treatment of liver cancers, especially those that cannot be treated with surgical resection ([@A34588R6]).

Although RFA and MWA are considered relatively safe and minimally invasive techniques, they can cause severe complications, such as intra-abdominal hemorrhage, liver abscess, biliary fistula, intestinal perforation, seeding, and skin burn; of these, liver abscess is one of the most common complications ([@A34588R7], [@A34588R8]). A good understanding of the complications that may occur post-treatment is the key to successful thermal ablation. Many studies have analyzed complications after RFA or MWA for liver cancer; however, most of these reports addressed clinical issues and treatment for liver abscesses following RFA. Few have undertaken statistical analyses of risk factors ([@A34588R9], [@A34588R10]). Although some studies have assessed risk factors for liver abscess formation after RFA, there has been little similar research on MWA ([@A34588R11], [@A34588R12]).

2. Objectives {#sec177323}
=============

The aim of this study was to retrospectively analyze the clinical records of 423 patients with liver cancer who underwent RFA or MWA, in order to determine the incidence of liver abscesses and to identify the risk factors for liver abscess formation.

3. Materials and Methods {#sec177332}
========================

3.1. Patient Selection {#sec177324}
----------------------

From July 2006 to July 2014, 423 patients with 767 liver tumors underwent a total of 691 thermal ablation therapy procedures at Qilu hospital of Shandong University and Weihai Municipal hospital. This retrospective study was approved by the ethics committee of Qilu hospital, allowing the investigators to review existing patient medical records. Because the study was retrospective, informed consent was waived. Informed consent was obtained for the original treatments of all patients. Both of the procedures (RFA and MWA) were explained to the patients, and the decision about which procedure to perform was based on the patient's economic condition, tumor size, and personal choice.

The inclusion criteria for the thermal ablation patients were hepatocellular carcinoma, intrahepatic cholangiocarcinoma or metastatic hepatic carcinoma, child-pugh class A or class B cirrhosis, or class C that transitioned to class B after treatment.

The exclusion criteria were an age of \> 80 years; an ASA score of grade IV or V, stable child-pugh class C cirrhosis, portal vein tumor thrombus or extrahepatic metastasis, platelet count of \< 50 × 10^9^/L, liver atrophy with a tumor that was too large and exceeded the normal liver size, esophagogastric variceal hemorrhage within the previous one month, tumor dissemination, bile duct or hepatic venous cancer embolus, severe functional disorders or major organs, disturbance of consciousness or cachexia, refractory ascites, coagulation disorders or severe blood diseases that could not be treated, and HIV or immunosuppression ([@A34588R12]).

3.2. Thermal Ablation Procedure {#sec177330}
-------------------------------

### 3.2.1. Instruments and Equipment {#sec177325}

Thermal ablations were performed using two cool-tip microwave treatment systems (Model MTC-3, Nanjing Forsea Microwave and Electron Institution, China; Model ECO-100A, Nanjing Yigao Company, China), and a cool-tip radiofrequency ablation instrument (Model No. CTRF-220, Tyco Valleylab) according to a previously described method ([@A34588R13]). The ablations were performed under real-time ultrasound guidance with a 3.5-MHz sector probe (TOSHIBA, Xario Prime Ultrasound, SSA-6000). Philips Brilliance 64 multi-slice spiral CT, Siemens second-generation double-source SOMATOM Definition Flash CT, and Siemens 1.5T and 3.0T magnetic resonance imaging (Magnetom Trio A Tim) were used to evaluate the procedure in each case.

### 3.2.2. Thermal Ablation Procedure {#sec177326}

All patients were treated under intravenous conscious sedation or local anesthesia. The procedures were performed by radiation intervention experts or surgical experts under strict sterile conditions in a dedicated interventional procedure room or operating room. The operators had extensive expertise and used real-time ultrasound, CT, or laparoscopy. Some procedures were performed via open abdominal surgery ([@A34588R14], [@A34588R15]). Briefly, the cool-tip microwave antenna or radiofrequency electrode was punctured percutaneously or directly into the center of each tumor ([@A34588R16], [@A34588R17]). During the ultrasound-guided procedure, there was no appropriate way of inserting into tumors close to diaphragmatic muscle, blocked by lung tissue. Therefore, it was necessary to inject 200 - 1,500 mL of physiological saline under the diaphragm to separate the tumors from the lung tissue. This method was also used to reduce organ injury when tumors were close to the gallbladder, heart, colon, stomach, or other organs ([@A34588R18], [@A34588R19]). A 21-gauge percutaneous ethanol injection (PEI) needle was inserted into the liver tumor through the same attachment hole, beside the echo probe, before the thermal ablation in some patients. Pure ethanol (99.8%) was then slowly injected into the tumor ([@A34588R20]). In order to prevent tumor seeding, hemorrhage, and biloma, ablation was also conducted within the intrahepatic needle passage before withdrawal.

### 3.2.3. Evaluation of Ablation Effects {#sec177327}

The ablation treatment was considered to be complete when the ablation zone (hyperechogenicity on ultrasound or a low-density region on CT) covered the whole tumor, and the ablative margin exceeded the edge of the tumor by 0.5 - 1 cm in three dimensions ([@A34588R1], [@A34588R2], [@A34588R6], [@A34588R7]). The effect of RFA or MWA was assessed with contrast-enhanced CT or MRI one month after the treatment. A reduction in alpha-fetoprotein levels also facilitated the assessment of effectiveness. If a remnant tumor or a new tumor was found on the CT or MR examination, supplementary treatments were performed.

### 3.2.4. Diagnosis of Liver Abscess {#sec177328}

The criteria for the diagnosis of liver abscesses after thermal treatment were as follows: 1) a fever of \> 38.5°C for more than 3 days, 2) a peripheral blood leukocyte count of \> 10 × 10^9^/L or \< 4×10^9^/L, 3) repeated chills and fever, 4) positive blood cultures or bacterial cultures by aspiration, and 5) septic shock. Peripheral enhancement of the ablation zone using CT and images showing pneumatosis in the ablation zone were considered diagnostic of a liver abscess if the patient met any of these five conditions.

### 3.2.5. Follow-Up {#sec177329}

Follow-up visits for all recorded patients were completed. The first post-ablation follow-up visit occurred after the first complaint of symptoms. The total time of follow-up was six months. Baseline clinical data were recorded, including a detailed evaluation of the ablation treatment, the presence of liver abscesses, the amount of time taken for the abscesses to develop, culture results, treatment methods, and outcomes.

3.3. Statistical Analysis {#sec177331}
-------------------------

We analyzed the incidence of liver abscesses after 691 thermal ablation procedures performed on 423 hepatic malignancy patients. We enrolled patients with multiple risk factors for liver abscess formation ([@A34588R21]-[@A34588R23]) into a risk factor group, and patients with no such risk factors into a control group. The data were presented in numbers (n), and the measurement data were represented by mean ± SD. The statistical methods of the chi-square (χ^2^) test and Fisher's exact probability test were used to compare the rates of liver abscesses between the different treatment methods.

The relationship between risk variables and liver abscess formation was analyzed with a multiple logistic regression analysis. A P value of \< 0.05 was considered to indicate statistical significance. The statistical analyses were performed with SPSS for Windows version 13.0 (SPSS Inc., Chicago, IL, USA).

4. Results {#sec177336}
==========

4.1. Baseline Clinical Characteristics of the Patients ([Table 1](#tbl45110){ref-type="table"}) {#sec177333}
-----------------------------------------------------------------------------------------------

###### Clinical Characteristics of Patients and Tumors^[a](#fn48268){ref-type="table-fn"}^

  Patient and Tumor Characteristics            Value
  -------------------------------------------- ---------------
  **Age (23 - 79)**                            57.0 ± 14.8
  **Gender**                                   
  Male/female                                  338/85
  **Type of tumor**                            
  HCC/MHC/IHCC                                 352/64/7
  **Quantity of tumors**                       767
  **Tumor diameter (0.5 - 8.5), cm**           3.5 ± 2.3
  **Tumor position (stage)**                   
  I/II/III/IV                                  3/143/151/138
  V/VI/VII/VIII                                88/152/43/48
  **First porta hepatic tumor**                46
  **Quantity of tumors**                       
  Solitary/multiple                            290/133
  **Child-Pugh classification**                
  A/B/C                                        268/138/17
  **Liver cirrhosis**                          282
  **Alcoholism history**                       32
  **Biliary tract disease**                    53
  **Cholangiocarcinoma**                       7
  **Diabetes mellitus**                        56
  **Ever underwent TACE**                      205
  **Preoperative blood biochemical indexes**   
  ALT, U/L                                     43.4 ± 2.8
  **Serum albumin, g/L**                       37.8 ± 3.2
  **Total bilirubin, μmol/L**                  27.2 ± 7.4
  **Preoperative antibiotic treatment**        106
  **Anesthesia**                               
  Local/intravenous                            260/163
  **Puncture method**                          
  Percutaneous/abdominal/laparoscopic          407/13/3
  **Thermal ablation process**                 
  RFA/MWA                                      385/306
  **Thermal ablation time, min**               16.2 ± 7.5
  **Diagnosis method of liver abscess**        
  CT/MR/puncture fluid culture                 9/2/1

^a^Values are expressed as No. or mean ± SD.

This study's patients included 338 males and 85 females between the ages of 23 and 79 years. Of the 423 patients analyzed, 172 were diagnosed by percutaneous biopsy; of these, 108 had hepatocellular carcinoma and 64 had hepatic metastasis. Two hundred and fifty-nine patients were diagnosed with typical imaging examinations and the presence of tumor markers. The median diameter of the tumors was 3.2 ± 2.3 cm (range 0.5 - 8.5 cm). With regard to tumor position, there were 332 tumors in the left lobe of the liver and 435 tumors in the right lobe. Forty-six patients had tumors in the porta hepatis region. Two hundred and ninety patients had solitary tumors, and 133 had multiple tumors. The numbers of patients with child-pugh class A, class B, and class C cirrhosis were 268, 138, and 17, respectively. Some class C patients became class B after drug treatment. Among the 423 patients, the numbers with liver cirrhosis, alcoholism, biliary tract disease, and diabetes mellitus were 282, 32, 53 and 56, respectively. A total of 205 patients underwent transcatheter arterial chemoembolization (TACE) 15 to 388 days before accepting ablation treatment. The biliary tract conditions associated with the patients included intrahepatic cholangiocarcinoma, bile duct stones, biliary stent placement, bilioenteric anastomosis, and endoscopic sphincterotomy (EST). The mean blood ALT value of the 423 patients was 43.4 ± 2.8 U/L, mean albumin was 37.8 ± 3.2 g/L, and mean total bilirubin was 27.2 ± 7.4 μmol/L. Before the operation, 106 patients had prophylactic antibiotic treatment. Local anesthesia was used in 260 patients and intravenous anesthesia was used in 163. The three puncture methods were percutaneous (n = 407), open abdominal (n = 13), and laparoscopy-assisted (n = 3). During the study period, 238 patients underwent 385 RFA procedures, and 185 patients underwent 306 MWA procedures. The mean thermal ablation time was 13.2 ± 7.3 minutes. The 12 patients with liver abscesses were diagnosed with contrast-enhanced CT (n = 9), contrast-enhanced MRI (n = 2), or cultures (n = 1).

4.2. Clinical Characteristics of Liver Abscess Patients (Table 2 and Figures 1 and 2) {#sec177334}
-------------------------------------------------------------------------------------

###### Baseline Characteristics of Patients With Liver Abscesses After Thermal Ablation

  Patient Sequence No. Basic Characteristics of Patients   1       2      3        4        5      6      7          8        9      10     11     12
  -------------------------------------------------------- ------- ------ -------- -------- ------ ------ ---------- -------- ------ ------ ------ --------
  **Gender**                                               Male    Male   Male     Female   Male   Male   Male       Female   Male   Male   Male   Male
  **Age, y**                                               70      64     66       68       50     56     44         55       72     76     57     65
  **Type of tumor**                                        HCC     MHC    HCC      HHC      ICC    HCC    HCC        ICC      HCC    HCC    ICC    HCC
  **Maximum tumor diameter, cm**                           4.5     2.2    4.6      3.2      2.4    5.5    2.4        2.3      3.0    2.8    3.5    8.5
  **Quantity of tumors**                                   1       3      2        1        1      1      3          1        1      2      2      2
  **Tumor position (segment)**                             IV      VIII   II,VII   IV       I      IV     VII,VIII   V        VI     IV,V   VI     II,III
  **Number of abscesses**                                  1       1      2        1        1      1      1          1        1      2      1      2
  **Alcoholism history**                                   Yes     No     No       No       No     Yes    No         No       No     No     No     No
  **Liver cirrhosis history**                              Yes     No     Yes      Yes      No     No     Yes        No       Yes    Yes    No     Yes
  **Biliary tract disease history**                        Yes     No     Yes      Yes      Yes    No     No         Yes      No     No     No     Yes
  **Diabetes mellitus history**                            No      Yes    No       No       Yes    No     Yes        No       No     Yes    Yes    No
  **First porta hepatis tumor**                            Yes     No     Yes      Yes      Yes    No     No         Yes      Yes    Yes    No     No
  **Ever underwent TACE**                                  Yes     No     No       No       No     Yes    No         No       Yes    No     No     Yes
  **Child-Pugh classification**                            B       A      B        C        A      A      C          A        B      C      A      B
  **ALT, U/L**                                             33      21     46       77       35     35     42         55       36     48     19     88
  **Serum albumin, g/L**                                   31      45     28       27       38     34     29         41       35     29     38     32
  **PT, %**                                                57      77     60       44       90     85     48         76       58     42     100    55
  **Total bilirubin, μmol/L**                              33.5    11.0   37.4     44.4     31.0   14.5   19.3       66.2     28.0   36.5   24.2   33.0
  **Preoperative antibiotic application**                  Yes     No     No       No       Yes    Yes    No         Yes      Yes    Yes    Yes    No
  **Postoperative antibiotic application**                 Yes     Yes    Yes      Yes      Yes    Yes    Yes        Yes      Yes    Yes    Yes    Yes
  **Anesthesia method**                                    Local   Int    Local    Int      Int    Loca   Local      Local    Int    Int    Int    Local
  **Puncture method**                                      Perc    Abd    Perc     Perc     Perc   Perc   Perc       Perc     Perc   Perc   Perc   Perc
  **Thermal ablation process**                             RFA     MWA    MWA      RFA      RFA    RFA    MWA        RFA      RFA    MWA    RFA    MWA
  **Thermal ablation time, min**                           36      11     29       20       32     40     9          14       21     22     58     65
  **Forming time, d**                                      55      37     3        32       5      3      28         12       6      20     4      1
  **Diagnostic method for abscess**                        CT      CT     CT       CT       MR     CT     CT         CT       CT     MR     MR     CT
  **Treatment method for abscess**                         Dra     Asp    Drug     Dra      Dra    Dra    Drug       Asp      Ope    Dra    Dra    Dra
  **Culture of causative agent**                           Pos     Neg    Pos      Pos      Neg    Pos    Neg        Neg      Pos    Neg    Pos    Pos
  **Outcome**                                              Rec     Rec    Rec      Death    Rec    Rec    Rec        Rec      Rec    Rec    Rec    Rec

Abbreviations: Abd, Abdominal; Asp, Aspiration; Dra, Drainage; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; Int, intravenous; MHC, metastatic hepatic carcinoma; Neg, negative; Ope, Operation; Perc, Percutaneous; Positive, Positive; Rec, Recovery.

![A 66-Year-Old Patient With Multiple Tumors Who Underwent RFA Via Percutaneous Puncture\
A, contrast-enhanced transverse CT obtained during the arterial phase shows irregular liver tumors (arrows) with maximum diameters of 4.6 cm and 3.5 cm, in liver segments VII and II, respectively. The latter tumor is located in the porta hepatis; B, on the 6th postoperative day, the patient underwent CT due to fever and chills. CT showed gas (triangular mark) forming in the low-attenuation ablation zone (arrow), indicating formation of a liver abscess. Cultures from puncture aspiration were positive *for Escherichia coli*; C, in addition to treatment with carbapenem antibiotics, catheter drainage (arrows) by percutaneous puncture under ultrasonic guidance was administered, and pus was aspirated. Four weeks later, the patient had recovered.](hepatmon-16-07-34588-g001){#fig32900}

![Patient with Child-Pugh Class-C Cirrhosis Who Underwent MWA Treatment of Liver Cancer With Percutaneous Puncture\
A, contrast-enhanced transverse CT imaging shows a 2.8 × 2.1 cm liver tumor (arrow) in segment IV and an irregular tumor (arrow) measuring approximately 2 × 1.5 cm, located close to the top of the right kidney in segment VI; B, after MWA, contrast-enhanced transverse CT imaging showed an oval low-density lesion (arrows); C, three days after the operation, hyperpyrexia occurred, with body temperature reaching 39.0°C. One week after the operation, contrast-enhanced CT showed an expanded ablation zone with pneumatosis, suggesting the formation of a liver abscess (arrows); D, catheter drainage of the liver abscess.](hepatmon-16-07-34588-g002){#fig32901}

Fifteen liver abscesses developed in 12 patients. These were identified using CT or MRI, except for one patient who had bacteria cultured from aspirated fluid in the ablation zone. Ten patients had fever and epigastric pain 3 - 28 days after the operation, and the other two had chills and tachycardia. For nine of these 12 patients, the ablation region and surrounding areas showed pneumatosis on CT images ([Figure 1B](#fig32900){ref-type="fig"} and [2B](#fig32900){ref-type="fig"}). Blood or aspiration cultures from seven of the 12 patients were positive. Seven of the 12 patients had been treated with intravenous or oral antibiotics before the operation. Four of the 15 abscesses were punctured following sonographic guidance for drainage. Seven abscesses were drained with 10 - 14F catheters ([Figure 2D](#fig32901){ref-type="fig"}) using sonographic guidance. All catheters were removed 10 - 50 days later, with no long-lasting sequelae. For some patients, drainage of multiple abscesses was performed ([Figure 1C](#fig32900){ref-type="fig"}). Two patients were treated only with antibiotics, while one patient needed surgical treatment after percutaneous drainage had failed. Eleven of the patients with liver abscesses recovered within 10 - 60 days, but the remaining one died due to septic shock.

4.3. Analysis of Incidence and Risk Factors of Liver Abscesses ([Tables 3](#tbl45112){ref-type="table"} and [4](#tbl45113){ref-type="table"}) {#sec177335}
---------------------------------------------------------------------------------------------------------------------------------------------

###### Influence of Treatment Method on Development of Liver Abscess After Thermal Ablation

                                                   RFA     MWA     Ablation Combined With PEI   Ablation Alone
  ------------------------------------------------ ------- ------- ---------------------------- ----------------
  **Number of patients with liver abscesses**      7       5       0                            12
  **Number of patients without liver abscesses**   378     299     73                           606
  **Total**                                        385     306     73                           618
  **χ** ^**2**^ **value**                          1.18    1.18    15.74                        15.74
  **P value**                                      0.812   0.812   0.0026                       0.0026

###### Relationships Between Risk Factor Variables and Abscess Formation After RFA and MWA Treatment^[a](#fn48269){ref-type="table-fn"}^

  Risk Factor Variables                 Incidence of Liver Abscess   P Value       Odds Ratio   Confidence Interval With Odds Ratio of 95%   
  ------------------------------------- ---------------------------- ------------- ------------ -------------------------------------------- ----------------
  **Gender**                            1.6                          2.4           0.4562       0.643                                        0.775 - 1.685
  Male/female                           9/569                        3/122                                                                   
  **Age**                               52.3 ± 10.2                  54.8 ± 11.3   0.8851       0.986                                        0.534 - 1.655
  **Tumor diameter, cm**                4.2 ± 2.6                    3.6 ± 3.2     0.2326       1.788                                        0.810 - 2.693
  **Serum ALT, U/L**                    42.4 ± 2.1                   36.5 ± 4.6    0.1536       2.012                                        0.698 - 2.874
  **Serum albumin, g/L**                32.2 ± 3.7                   38.1 ± 2.4    0.4605       0.651                                        0.513 - 1.725
  **Total bilirubin, μmol/L**           29.6 ± 7.6                   25.3 ± 6.4    0.6664       0.734                                        0.438 - 1.654
  **Thermal ablation time, min**        17.0 ± 4.3                   15.8 ± 6.6    0.6544       0.729                                        0.502 - 1.678
  **Tumor position**                    1.7                          1.8           0.7966       0.925                                        0.668 - 1.774
  left lobe/right lobe                  5/301                        7/390                                                                   
  **Multiple tumors**                   2.2                          1.6           0.5218       1.378                                        0.564 - 1.838
  Ratio                                 4/184                        8/507                                                                   
  **Child-Pugh Class B and C**          3.6                          0.6           0.0386       6.300                                        1.372 - 18.802
  Ratio                                 8/223                        3/468                                                                   
  **Liver cirrhosis**                   1.7                          1.9           0.6977       0.897                                        0.614 - 1.662
  Ratio                                 9/532                        3/159                                                                   
  **Alcoholism history**                2.9                          1.6           0.1313       1.832                                        0.649 - 3.328
  Ratio                                 2/68                         10/623                                                                  
  **First porta hepatis tumor**         13.0                         1.0           0.0123       13.370                                       1.233 - 88.232
  Ratio                                 6/46                         6/615                                                                   
  **Biliary tract disease**             6.7                          1.0           0.0305       6.764                                        1.112 - 22.855
  Ratio                                 6/89                         6/602                                                                   
  **Intrahepatic cholangiocarcinoma**   42.9                         1.3           0.0015       32.76                                        1.975 - 96.741
  Ratio                                 3/7                          9/688                                                                   
  **Diabetes mellitus**                 6.5                          1.1           0.0344       5.696                                        1.020 - 20.374
  Ratio                                 5/77                         7/614                                                                   
  **Multiple tumors**                   2.1                          1.5           0.5524       1.399                                        0.578 - 1.902
  Ratio                                 6/288                        6/403                                                                   
  **Ever underwent TACE**               1.3                          2.1           0.3636       0.597                                        0.522 - 1.688
  Ratio                                 4/315                        8/376                                                                   
  **Preoperative antibiotics**          2.8                          1.5           0.3321       1.840                                        0.638 - 2.965
  Ratio                                 3/106                        9/585                                                                   
  **Local anesthesia**                  1.5                          2.2           0.4950       0.703                                        0.570 - 1.655
  Ratio                                 7/460                        5/231                                                                   
  **Percutaneous puncture**             1.6                          3.8           0.0612       0.430                                        0.522 - 1.587
  Ratio                                 11/665                       1/26                                                                    
  **Tumor in situ progression**         1.4                          1.8           0.7812       0.819                                        0.465 - 1.887
  Ratio                                 1/69                         11/622                                                                  

^a^Values are expressed as mean ± SD or %.

Among the 385 RFA procedures, liver abscesses developed in seven cases (1.9%), while among the 306 MWA procedures, liver abscesses developed in five cases (1.6%) (P = 0.8212). There were no liver abscesses in the 73 patients who underwent thermal ablation combined with PEI. This was significantly lower than in the non-combined treatment group (1.9%) (P = 0.014). Liver abscesses occurred in nine (1.6%) of the 569 procedures performed on male patients, and in three (2.4%) of the 122 procedures performed on female patients. Of the 301 procedures on patients with left lobe tumors, five (1.6%) developed liver abscesses. Of the 390 procedures on patients with right lobe tumors, seven (1.8%) developed liver abscesses. In the liver abscess group, the mean tumor diameter was 4.2 ± 2.6 cm, the mean age of the patients was 52.3 ± 10.2 years, and the serum ALT, albumin, and total bilirubin levels before the operation were 42.4 ± 2.1 U/L, 32.2 ± 3.7 g/L, and 29.6 ± 7.6 μmol/L, respectively. The mean duration of thermal ablation in this group was 14.0 ± 4.3 minutes. In the group without liver abscesses, the mean tumor diameter was 3.6±3.2 cm and the mean age was 54.8 ± 11.3 years. The mean serum ALT, albumin, and total bilirubin levels before the operation in this group were 36.5 ± 4.6 U/L, 38.1 ± 2.4 g/L, and 25.3 ± 6.4 μmol/L, respectively, and the mean duration of thermal ablation was 10.8 ± 6.6 minutes. Liver abscesses occurred in seven (4.0%) of the 223 patients with child-pugh class B and child-pugh class C cirrhosis, in two (2.9%) of the 68 that presented with alcoholic liver disease, in six (16.7%) of the 36 that had porta hepatis tumors, and in six (6.7%) of the 89 with biliary tract disease. Among the biliary tract disease patients, there were three with intrahepatic cholangiocarcinoma, one who underwent bilioenteric anastomosis, one with bacterial-infected cholelithiasis, and one who underwent sphincterotomy and endoscopic retrograde biliary drainage. Liver abscesses also developed in three (42.8%) of the seven patients with intrahepatic cholangiocarcinoma, five (6.5%) of the 77 with diabetes mellitus, six (2.1%) of the 288 with multiple tumors, 11 (1.6%) of the 655 with percutaneous punctures, one (1.4%) of the 69 with local tumor progression, and four (1.3%) of the 315 who underwent TACE 15 - 388 days before thermal ablation. The analysis of the potential risk factors showed that child-pugh class B or class C cirrhosis (P = 0.0486), biliary tract disease (P = 0.0305), diabetes mellitus (P = 0.0344), and porta hepatis tumors (P = 0.0123) were significant risk factors for liver abscess formation. Intrahepatic cholangiocarcinoma (P = 0.0015) was observed to be an independent risk factor of liver abscess formation associated with biliary tract disease.

5. Discussion {#sec177337}
=============

Previous studies have reported that the incidence of liver abscess was approximately 0.3%--2.0% after RFA ([@A34588R20], [@A34588R21]) and approximately 0.5% - 3.0% after MWA ([@A34588R17], [@A34588R24]). The current study demonstrated no obvious difference between RFA and MWA in the incidence of liver abscess. Knowledge pertaining to the risk factors for liver abscess formation after thermal ablation is likely to be valuable in reducing the occurrence of this complication, shortening hospitalization periods, and reducing the associated mortality rate.

Similar to the syndrome that occurs after TACE, fever can occur after thermal ablation ([@A34588R25]). Generally, body temperature reaches a peak three days after the procedure and then gradually declines. If the fever lasts longer than two weeks, or the hyperpyrexia (body temperature of \> 38.5°C) lasts longer than three days, the possibility of liver abscess formation should be considered ([@A34588R26]). The mechanism by which patients develop a liver abscess after thermal ablation is not well understood. The most common routes of infection resulting in bacterial liver abscesses include the bile ducts, portal vein, hepatic artery, and direction invasion from other infected cavities, especially the biliary tract ([@A34588R27]). Operations on the biliary tract, such as bilioenteric anastomosis, may damage the integrity of the extrahepatic or intrahepatic bile duct epithelium and allow retrograde passage of bacteria from the intestinal tract into the liver, resulting in proliferation in the ablation region. de Baere et al. ([@A34588R28]) demonstrated that liver abscesses developed in seven out of 582 patients following thermal ablation. All three patients who had undergone bilioenteric anastomosis developed liver abscesses. This is likely due to injury to the biliary tract, allowing intestinal bacteria to contaminate the necrosis zone after ablation ([@A34588R29]). In our study, the incidence of liver abscess was as high as 6.7%, which indicated that biliary duct disease is related to liver abscess formation after thermal ablation. We suspect that along with bilioenteric anastomosis, the presence of bile duct stones, biliary tract stent implantation, intrahepatic cholangiocarcinoma, and other bile duct diseases, such as biliary abnormalities, may be important risk factors ([@A34588R23]).

Intrahepatic cholangiocarcinoma usually causes obstruction of the biliary tract because of inadequate drainage of bile, which increases the probability of liver abscess due to retrograde infection. Kim et al. ([@A34588R30]) reported that liver abscesses occurred in only one (5.0%) of 20 intrahepatic cholangiocarcinoma patients undergoing hepatectomy after ablation. In the current study, three (42.8%) of seven patients with intrahepatic cholangiocarcinoma developed abscesses after ablation procedures because of increased risk due to ascending biliary infection.

Another mechanism of liver abscess formation is biloma followed by concurrent infection ([@A34588R31], [@A34588R32]). When the tumor is located in the porta hepatis or the distance between the tumor and the main bile duct is \< 1 cm, injury to the main bile duct can be inevitable because it is necessary to create a 0.5 - 1 cm ablation boundary beyond the range of the tumor. This can result in bilomas connected to the main bile duct in the ablation zone, and liver abscesses may occur due to retrograde infection. This may explain why abscesses occurred in 16.7% of patients who had porta hepatis tumors in the present study. Some reports have stated that RFA and MWA treatments should not be applied to tumors in the center of the porta hepatis ([@A34588R33]).

After analyzing the 77 patients with diabetes mellitus in this study, we found that diabetes might have been related to the development of abscesses in five of them. A study by Thomsen et al. on a large cohort in Denmark showed a high incidence of liver abscesses after RFA for hepatic malignancy in patients with diabetes mellitus ([@A34588R34]). Liang et al. analyzed complications associated with 1,136 patients after MWA, and found that out of five patients with liver abscesses, two had underlying diabetes mellitus (40%) ([@A34588R10]). Hyperglycemia enhances bacterial growth, inhibits the cellular immune response, and weakens the bactericidal strength of the hematological system, possibly facilitating the ability of bacteria to cause infection, to reproduce, and to form liver abscesses.

A study by Choi et al. showed that child-pugh class B cirrhosis was not a risk factor for liver abscess formation after RFA ([@A34588R22]). In contrast, the current analysis demonstrated that patients with child-pugh class B or class C cirrhosis had a higher rate of liver abscesses than patients at the class A stage, and one patient with class C cirrhosis died of septicemia. Although active measures were adopted, there were two cases of liver abscesses, with the incidence reaching 11.7%. This might be one of the reasons the current results differed from previous reports ([@A34588R22]). In Europe, patients with child-pugh class C cirrhosis are recommended to receive only palliative support, including pain, nutritional, and psychological management ([@A34588R35]). However, in China, many patients with child-pugh class C cirrhosis choose thermal ablation even after receiving detailed information about its risks versus benefits, as there is no other effective therapy except for liver transplantation, which is expensive. In addition, donor livers are frequently of limited availability.

Apart from mitigating the risk factors highlighted above, it has been suggested that treatment combining thermal ablation with PEI could reduce the incidence of liver abscesses due to micro-bile duct sclerosis caused by anhydrous alcohol ([@A34588R20]). This may inhibit migration and infection by bacteria. Additionally, PEI in tumors close to the bile duct might increase the therapeutic efficacy while decreasing thermal injury to the bile duct ([@A34588R35]), thus reducing the incidence of liver abscesses.

Although it is debatable whether antibiotics should be given to all patients who receive thermal ablations, most reports suggest that those with the highest risk of infection should be given prophylactic antibiotics ([@A34588R30], [@A34588R31]). Hoffmann et al. applied broad-spectrum antibiotic treatment to patients undergoing bilioenteric anastomosis operations, and liver abscesses developed in only a single patient who underwent TACE ([@A34588R36]). In our study, liver abscesses occurred in two (3%) out of 66 patients with biliary tract disease who had received prophylactic antibiotics, and in four (17.3%) out of 23 patients who did not receive prophylactic antibiotics. This suggests that the use of prophylactic antibiotics is necessary for patients with a high risk of infection, especially those undergoing biliary tract procedures. Further prospective studies are required to determine the effectiveness of aggressive antibiotic use.

Our study had some limitations. First, the data were derived from two hospitals, with different environments, equipment, and doctor expertise. Second, we did not conduct a more detailed analysis according to tumor size. For example, the incidence of liver abscesses in patients with varying tumor diameters may be different. Finally, because this study was a retrospective analysis, the frequency of thermal ablations could not be controlled, and there may have been selection bias.

In conclusion, after thermal ablation of liver cancer, the overall incidence of liver abscesses was relatively low, and there was no significant difference in the rate of abscesses between the RFA and MWA treatments. Our results suggest that operators should pay more attention to the risk factors for abscess formation in patients with biliary tract disease, child-pugh class B and class C cirrhosis, diabetes, and tumors in the porta hepatis. For high-risk patients, we recommend following the appropriate indications for thermal ablation.
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